The Effect of Transcranial Direct Stimulation on Cognitive Functions of Healthy Adults

Sponsor

Medipol University (Other)

Overall Status

Completed

CT.gov ID

NCT04873804

Collaborator

(none)

Enrollment

Locations

Arms

Actual Duration (Months)

28.5

Patients Per Site

3.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Background: Transcranial direct current stimulation(tDCS) has been used to improve cognitive functions in healthy young adults.

Purpose: To investigate the effect of TDCS application on different cortex regions on cognitive function.

Methods: Sixty individuals aged 18-30 were included in the study. The participants were randomly divided into the left dorsolateral prefrontal cortex (Left DLPFC Group)(n=20), the right posterior parietal cortex (Right PPC Group)(n=20), and the sham group (Sham Group)(n=20). tDCS was applied for 20 minutes on weekdays for 2 weeks. The participants were evaluated in terms of cognitive functions with Neuropsychometric Test Battery before and after treatment.

Condition or Disease	Intervention/Treatment	Phase
Cognitive Symptom Healthy	Other: Transcranial Direct Current Stimulation	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

57 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Participant)

Primary Purpose:

Diagnostic

Official Title:

The Effect Of Transcranial Direct Stimulation Applied To The Dorsolateral Prefrontal Cortex And Posterior Parietal Cortex İn Cognitive Function, Mood And Proprioception İn Healthy Adults

Actual Study Start Date :

Oct 10, 2019

Actual Primary Completion Date :

May 10, 2020

Actual Study Completion Date :

Jun 10, 2020

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: LEFT DLPFC The anode electrode of tDCS was applied to the left DLPFC and the cathode electrode was connected to the contralateral shoulder.	Other: Transcranial Direct Current Stimulation The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
Active Comparator: RİGHT PPC The anode electrode of tDCS was applied to the right PPC and the cathode electrode was connected to the contralateral shoulder.	Other: Transcranial Direct Current Stimulation The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
Sham Comparator: Sham Placebo was applied by placing the electrodes in the right PPC and left DLPFC without applying current.	Other: Transcranial Direct Current Stimulation The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.

Arm

Intervention/Treatment

Active Comparator: LEFT DLPFC

The anode electrode of tDCS was applied to the left DLPFC and the cathode electrode was connected to the contralateral shoulder.

Other: Transcranial Direct Current Stimulation

The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.

Active Comparator: RİGHT PPC

The anode electrode of tDCS was applied to the right PPC and the cathode electrode was connected to the contralateral shoulder.

Other: Transcranial Direct Current Stimulation

Sham Comparator: Sham

Placebo was applied by placing the electrodes in the right PPC and left DLPFC without applying current.

Other: Transcranial Direct Current Stimulation

Outcome Measures

Primary Outcome Measures

Neuropsychiatric Test Battery [3 weeks]
It is a test battery for getting detailed information about general cognitive status.
Beck Depression Scale [3 weeks]
It measures the symptoms seen in depression such as emotional, cognitive and motivational. It includes 21 items determine a behavioral feature related to depression. Items are numbered from 0 to 3. The goal is to objectively break down the degree of symptoms. The total score of all answers is calculated as follows: 0 to 9 points: Minimally depressive symptoms 10 to 16 points: Mild depressive symptoms Between 17 and 29 points: Moderate depressive symptoms Between 30 and 63 points: Severe depressive symptoms

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 30 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

being 18-30 years old

Exclusion Criteria:

alcohol and substance addiction
previous mental illness
having mental and cognitive problems
a history of head trauma
having cardiovascular disease.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Damla Ören	Istanbul		Turkey	34000
2	Medipol Mega Hospital	Istanbul		Turkey	34000

Sponsors and Collaborators

Medipol University

Investigators

Principal Investigator: Miray Budak, PhD, Medipol University
Study Chair: Lutfu Hanoglu, PhD, Medipol University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Damla Ören, Physiotherapist MSc, Medipol University

ClinicalTrials.gov Identifier:

NCT04873804

Other Study ID Numbers:

tDCS on DLPFC and PPC

First Posted:

May 5, 2021

Last Update Posted:

May 5, 2021

Last Verified:

May 1, 2021

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Damla Ören, Physiotherapist MSc, Medipol University

tDCS

Dorsolateral Prefrontal Cortex

Posterior Parietal Cortex

Cognitive Function

Additional relevant MeSH terms:

Neurobehavioral Manifestations

Study Results

No Results Posted as of May 5, 2021